Lung Health Foundation’s new Canadian COPD Performance Index finds significant shortfalls in COPD care across the country, driven by missing data, workforce shortages and no national strategy. Here’s ...

For the long-term management and treatment of moderate to severe COPD ...

Pulmonary and critical care medicine has long carried the reputation as one of the most demanding medical specialties.

Patients with COPD with raised eosinophil levels can benefit from biologic treatment with dupilumab, producing consistent ...

A diagnosis of chronic obstructive pulmonary disease (COPD) might bring fear and uncertainty. But Leah Knabe, APRN, a family ...

No lecture. No shaming. No “I told you so.” Just another chance to do better with what I’d been given. And this time, I rose ...

Lupin’s Formoflo-G® MDI combines glycopyrronium bromide, formoterol fumarate and fluticasone propionate in a twice-daily ...

Emily learned from an early age the devastation lung disease can have on a family. Her grandmother passed away at 61 years old from emphysema when she was just a child. Then, in 2013, her mother was ...

Among neurocritical patients, older age and COPD are significant risk factors for VAP, according to a systematic review and meta-analysis.

For the first time, U.S. CardioMEMS patients will be able to view pulmonary artery pressure (PAP) readings and receive personalized medication updates through the CardioGuide HF App Rising PAP can ...

Replicate phase 3 trials show the IL-33-targeting monoclonal antibody reduces moderate and severe exacerbations regardless of blood eosinophil levels or smoking status.

Lupin Limited launched Formoflo-G® MDI, a fixed-dose triple-combination metered-dose inhaler (MDI) for the management of ...